More Information About - Spirocard 50 mg Tab. - 50 mg
Description
Generic Name
Spironolactone
Precaution
Patient at risk of developing hyperkalaemia and acidosis, w/ DM. Renal and hepatic impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and somnolence, if affected do not drive or operate machinery. Monitoring Parameters Monitor serum electrolytes periodically; BP, renal function.
Lactation: Metabolite excreted into breast milk; discontinue breastfeeding or do not use drug
Indication
Oedema, Hirsutism, Hypertension, Hepatic cirrhosis w/ ascites and oedema, Hyperaldosteronism, Severe CHF, Hypokalaemia
Contra Indication
Anuria, hyperkalaemia, acute or progressive renal insufficiency. Addison's disease.
Dose
N/A
Side Effect
Drowsiness, dizziness, headache, lethargy, leg cramps, GI disturbances (e.g. diarrhoea, cramps), ataxia, mental confusion, rashes, pruritus, alopecia, hyponatraemia, electrolyte disturbances, gynaecomastia, hirsutism, menstrual irregularities, breast pain, deepening of the voice, impotence, leucopenia (including agranulocytosis), thrombocytopenia, transient elevation in BUN concentration. Rarely, breast enlargement.
Potentially Fatal: Hyperkalaemia.
Pregnancy Category
Name :
Not Classified
Description
FDA has not yet classified the drug into a specified pregnancy category.
Mode of Action
Spironolactone acts on the distal renal tubules as a competitive antagonist of aldosterone. It increases the excretion of sodium chloride and water while conserving potassium and hydrogen ions.
Interaction
Increased risk of hyperkalaemia w/ other K-sparing diuretics or K supplements, ACE inhibitors, angiotensin II receptor antagonists, trilostane, heparin, LMWH. Increased risk of nephrotoxicity w/ ciclosporin, NSAIDs. Increased risk of lithium toxicity. May reduce ulcer-healing properties of carbenoxolone. May increase serum level of digoxin. May reduce vascular response to norepinephrine. Concurrent use w/ colestyramine may cause hyperkalaemic metabolic acidosis. Potentiation of orthostatic hypotension may occur w/ barbiturates or narcotics.
Potentially Fatal: May enhance hyperkalaemic effect w/ eplerenone. Increased risk of lithium toxicity when used concurrently.
Pregnancy Category Note
Pregnancy
Based on mechanism of action and findings in animal studies, spironolactone may affect sex differentiation of the male during embryogenesis; rat embryofetal studies report feminization of male fetuses and endocrine dysfunction in females exposed to spironolactone in utero
Limited available data did not demonstrate an association of major malformations or other adverse pregnancy outcomes with spironolactone; risks may occur to the mother and fetus associated with heart failure, cirrhosis, and poorly controlled hypertension during pregnancy
Potential risk to the male fetus due to antiandrogenic properties of spironolactone; avoid spironolactone in pregnant women or advise a pregnant woman of the potential risk to a male fetus
Disease-associated maternal and embryo/fetal risks
Pregnant women with CHF are at increased risk for preterm birth; stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester; closely monitor pregnant patients with CHF
Pregnant women with symptomatic cirrhosis generally have poor outcomes (eg, hepatic failure, variceal hemorrhage, preterm delivery, fetal growth restriction, and maternal death); pregnant women with cirrhosis of the liver should be monitored and managed accordingly
Hypertension in pregnancy increases the maternal risk for preeclampsia, gestational diabetes, premature delivery, and delivery complications (eg, need for cesarean delivery, postpartum hemorrhage); hypertension increases the fetal risk for intrauterine growth restriction and death
Lactation
Not present in breastmilk; however, limited data from a lactating woman at 17 days postpartum reports the presence of the active metabolite, canrenone, in human breast milk in low amounts that are expected to be clinically inconsequential; in this case, there were no adverse effects reported for the breastfed infant after short term exposure to spironolactone; however, long term effects on a breastfed infant are unknown; there are no data on spironolactone effects on milk production
Consider the developmental and health benefits of breastfeeding along with the mother?s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Adult Dose
Oral
Oedema
Adult: Initially, 100 mg daily, may adjust dose according to response up to 400 mg daily.
Hepatic cirrhosis with ascites and oedema
Adult: Depending on urinary Na/K ratio: If >1: Initially, 100 mg daily; if <1: Initially, 200-400 mg daily.
Diagnosis of primary hyperaldosteronism
Adult: Long test: 400 mg daily for 3-4 wk. Short test: 400 mg daily for 4 days.
Preoperative management of hyperaldosteronism
Adult: 100-400 mg daily. Long-term maintenance in the absence of surgery: Admin the lowest effective dose.
Hypertension
Adult: As monotherapy: Initially, 50-100 mg in 1-2 divided doses, may adjust dose after 2 wk.
Severe congestive heart failure
Adult: As adjunct: Initially, 25 mg once daily to max 50 mg daily. May reduce to 25 mg every other day if 25 mg once daily dose is not tolerated.
Diuretic-induced hypokalaemia
Adult: 25-100 mg daily.
Hirsutism
Women with hirsutism
Adult: 50-200 mg qDay or divided q12hr
Elderly: Initiate w/ the lowest dose then titrate upward if needed.
Child Dose
Oral
Hepatic cirrhosis with ascites and oedema
Child: Initially, 3 mg/kg given in divided doses, may adjust according to response.
Diagnosis of primary hyperaldosteronism
Child: Initially, 3 mg/kg given in divided doses, may adjust according to response.
Preoperative management of hyperaldosteronism
Child: Initially, 3 mg/kg given in divided doses, may adjust according to response.
Severe congestive heart failure
Child: Initially, 3 mg/kg given in divided doses, may adjust according to response.
Renal Dose
Renal impairment
CrCl >50 mL/min/1.73 m?: 12.5-25 mg qDay; use maintenance dose of 25 mg qDay or q12hr after 4 weeks of treatment with potassium <5 mEq/L
CrCl 30-49 mL/min/1.73 m?: 12.5 mg qDay or every other day; use maintenance dose of 12.5-25 mg qDay after 4 weeks of treatment with potassium <5 mEq/L
CrCl <30 mL/min/1.73 m?: Avoid use
Administration
Should be taken with food.
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.